Pediatric Dose Selection and Utility of PBPK in Determining Dose
Interest in determining safe and efficacious doses for drug administration in pediatric patients has increased dramatically in recent years. However, published pediatric clinical studies have failed to increase proportionally with adult clinical study publications. In order to assess the current state of pediatric dose determination and the supporting role of physiologically based pharmacokinetic modeling and simulation in determining pediatric dose, the pediatric clinical literature (2006–2016) and case examples of pediatric PBPK modeling efforts were reviewed. The objective of this assessment was to investigate the contribution of PBPK to our understanding of the differences between children and adults, which lead to differences in drug dose. Pediatric and adult dose data were available for 31 small molecule drugs. In general, pediatric dose was well-correlated with adult data, with an apparent tendency for higher body weight- or body surface area-normalized pediatric dose. Overall performance of pediatric PBPK modeling approaches was considered to adequately predict observed data. However, model performance was dependent upon age group simulated, with approximately half of neonatal predictions falling outside of 1.5-fold of observed. In conclusion, there is a clear need for further refinement of starting dose in pediatric phase 1 studies, and utilization of PBPK could lead to reduced numbers of patients required to establish safe and efficacious doses in the pediatric population.
KEY WORDSclinical PBPK pediatric phase 1 oncology
- 2.Ren Z, Zajicek A. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: what can the obstetric community learn from the pediatric experience? Semin Perinatol. 2015;39(7):530–1. https://doi.org/10.1053/j.semperi.2015.08.006.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Wagner C, Pan Y, Hsu V, Grillo JA, Zhang L, Reynolds KS, et al. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration. Clin Pharmacokinet. 2015;54(1):117–27. https://doi.org/10.1007/s40262-014-0188-4.CrossRefPubMedGoogle Scholar
- 12.Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005;59(6):691–704. https://doi.org/10.1111/j.1365-2125.2004.02225.x.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Somani AA, Thelen K, Zheng S, Trame MN, Coboeken K, Meyer M, et al. Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds. Br J Clin Pharmacol. 2016;81(1):137–47. https://doi.org/10.1111/bcp.12752.CrossRefPubMedGoogle Scholar
- 23.Rasool MF, Khalil F, Laer S. Predicting stereoselective disposition of carvedilol in adult and pediatric chronic heart failure patients by incorporating pathophysiological changes in organ blood flows-a physiologically based pharmacokinetic approach. Drug Metab Dispos 2016;44(7):1103–1115. doi: https://doi.org/10.1124/dmd.115.068858.
- 24.T'Jollyn H, Snoeys J, Vermeulen A, Michelet R, Cuyckens F, Mannens G, et al. Physiologically based pharmacokinetic predictions of tramadol exposure throughout pediatric life: an analysis of the different clearance contributors with emphasis on CYP2D6 maturation. AAPS J. 2015;17(6):1376–87. https://doi.org/10.1208/s12248-015-9803-z.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Thai HT, Mazuir F, Cartot-Cotton S, Veyrat-Follet C. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel. Br J Clin Pharmacol. 2015;80(3):534–47. https://doi.org/10.1111/bcp.12702.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Zhou W, Johnson TN, Bui KH, Cheung SYA, Li J, Xu H, al-Huniti N, Zhou D Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther 2017. doi: https://doi.org/10.1002/cpt.905.
- 28.Ginsberg G, Hattis D, Russ A, Sonawane B. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children’s risks from environmental agents. J Toxicol Environ Health A. 2004;67(4):297–329. https://doi.org/10.1080/15287390490273550.CrossRefPubMedGoogle Scholar
- 30.Jiang XL, Zhao P, Barrett JS, Lesko LJ, Schmidt S. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol. 2013;2(10):e80. https://doi.org/10.1038/psp.2013.55.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Ogungbenro K, Aarons L, Cresim, Epi CPG. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate. J Pharmacokinet Pharmacodyn 2014;41(2):173–185. doi: https://doi.org/10.1007/s10928-014-9355-3.
- 33.Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet. 2011;50(9):613–23. https://doi.org/10.2165/11592640-000000000-00000.CrossRefPubMedGoogle Scholar
- 35.Yang X, Morris SM, Gearhart JM, Ruark CD, Paule MG, Slikker W, Jr., Mattison DR, Vitiello B, Twaddle NC, Doerge DR, Young JF, Fisher JW Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. PLoS One 2014;9(9):e106101. doi: https://doi.org/10.1371/journal.pone.0106101.